Episode Details
Back to Episodes
Bay Area based Shennon Biotechnologies announced a new CEO today, Cyril Konto, and a $12M raise to advance its T-cell engager programs
Published 1 day, 18 hours ago
Description
It also announced that the three lead programs will go after small cell lung cancer, ovarian, and hepatocellular carcinoma, though it did not disclose specific targets.